FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wesley Tanaka

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Ira Gantz; Ngozi Erondu; Madhuja Mallick; Bret Musser; Rajesh Krishna; Wesley Tanaka; Karen Snyder; Cathy Stevens; Mark A Stroh; Haiyuan Zhu; John A Wagner; Douglas J MacNeil; Steven B Heymsfield; John M Amatruda
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
Gary A Herman; Arthur Bergman; Cathy Stevens; Paul Kotey; Bingming Yi; Peng Zhao; Bruno Dietrich; George Golor; Andreas Schrodter; Bart Keymeulen; Kenneth C Lasseter; Mark S Kipnes; Karen Snyder; Deborah Hilliard; Michael Tanen; Caroline Cilissen; Marina De Smet; Inge De Lepeleire; Kristien van Dyck; Amy Qiu Wang; Wei Zeng; Michael J Davies; Wesley Tanaka; Jens J Holst; Carolyn F Deacon; Keith M Gottesdiener; John A Wagner
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Gary A Herman; Arthur Bergman; Fang Liu; Cathy Stevens; Amy Qiu Wang; Wei Zeng; Li Chen; Karen Snyder; Deborah Hilliard; Michael Tanen; Wesley Tanaka; Alan G Meehan; Kenneth C Lasseter; Stacy C Dilzer; Robert Blum; John A Wagner
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wesley Tanaka (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Ira Gantz; Ngozi Erondu; Madhuja Mallick; Bret Musser; Rajesh Krishna; Wesley Tanaka; Karen Snyder; Cathy Stevens; Mark A Stroh; Haiyuan Zhu; John A Wagner; Douglas J MacNeil; Steven B Heymsfield; John M Amatruda
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
The Journal of clinical endocrinology and metabolism 2007;92(5):1754-7.
2006: Gary A Herman; Arthur Bergman; Cathy Stevens; Paul Kotey; Bingming Yi; Peng Zhao; Bruno Dietrich; George Golor; Andreas Schrodter; Bart Keymeulen; Kenneth C Lasseter; Mark S Kipnes; Karen Snyder; Deborah Hilliard; Michael Tanen; Caroline Cilissen; Marina De Smet; Inge De Lepeleire; Kristien van Dyck; Amy Qiu Wang; Wei Zeng; Michael J Davies; Wesley Tanaka; Jens J Holst; Carolyn F Deacon; Keith M Gottesdiener; John A Wagner
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2006;91(11):4612-9.
2006: Gary A Herman; Arthur Bergman; Fang Liu; Cathy Stevens; Amy Qiu Wang; Wei Zeng; Li Chen; Karen Snyder; Deborah Hilliard; Michael Tanen; Wesley Tanaka; Alan G Meehan; Kenneth C Lasseter; Stacy C Dilzer; Robert Blum; John A Wagner
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Journal of clinical pharmacology 2006;46(8):876-86.
2006: Katelijn Decochez; Ronda K Rippley; Jutta L Miller; Marina De Smet; Kerri X Yan; Zissi Matthijs; Kerry Riffel; Hengchang Song; Haiyuan Zhu; Hannah O Maynor; Wesley Tanaka; Amy O Johnson-Levonas; Michael J Davies; Keith M Gottesdiener; Bart Keymeulen; John A Wagner
A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.
Drugs in R&D 2006;7(2):99-110.
2006: Arthur J Bergman; Cathy Stevens; YanYan Zhou; Bingming Yi; Martine Laethem; Marina De Smet; Karen Snyder; Deborah Hilliard; Wesley Tanaka; Wei Zeng; Michael Tanen; Amy Qiu Wang; Li Chen; Gregory A Winchell; Michael J Davies; Steven Ramael; John A Wagner; Gary A Herman
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Clinical therapeutics 2006;28(1):55-72.
2005: Gary A Herman; Cathy Stevens; Kristien van Dyck; Arthur Bergman; Bingming Yi; Marina De Smet; Karen Snyder; Deborah Hilliard; Michael Tanen; Wesley Tanaka; Amy Qiu Wang; Wei Zeng; Donald G Musson; Gregory A Winchell; Michael J Davies; Steven Ramael; Keith M Gottesdiener; John A Wagner
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Clinical pharmacology and therapeutics 2005;78(6):675-88.
2000: Anne Van Hecken; Jules I Schwartz; M Depré; Inge De Lepeleire; aimee dallob; Wesley Tanaka; K Wynants; A Buntinx; Jef Arnout; Peggy H Wong; David L Ebel; Barry J Gertz; Paul De Schepper
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Journal of clinical pharmacology 2000;40(10):1109-20.
1999: aimee dallob; Inge De Lepeleire; Anne Van Hecken; A Porras; M Depré; S Mukhopadhyay; M Flynn; L Wildonger; Keith M Gottesdiener; Wesley Tanaka; Paul De Schepper
Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1999;48 Suppl 2():S130-1.
1999: LA Drake; Maria Hordinsky; VC Fiedler; James M Swinehart; WALTER UNGER; P C Cotterill; Diane M Thiboutot; Nicholas Lowe; C Jacobson; David A Whiting; S Stieglitz; S J Kraus; E I Griffin; D Weiss; P Carrington; C Gencheff; G W Cole; David M Pariser; Edwin S Epstein; Wesley Tanaka; aimee dallob; K Vandormael; LA Geissler; Joanne Waldstreicher
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Journal of the American Academy of Dermatology 1999;41(4):550-4.
1997: Jules I Schwartz; Wesley Tanaka; D Z Wang; David L Ebel; LA Geissler; aimee dallob; Barry Hafkin; Barry J Gertz
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
The Journal of clinical endocrinology and metabolism 1997;82(5):1373-7.
1995: Toshihiko Uematsu; Mitsutaka Kanamaru; Kazuhiro Kosuge; K Hara; N Uchiyama; N Takenaga; Wesley Tanaka; B S Friedman; Mitsuyoshi Nakashima
Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
British journal of clinical pharmacology 1995;40(1):59-66.
1995: S M Cohen; J G Werrmann; G H Rasmusson; Wesley Tanaka; P F Malatesta; Srinivasa Prahalada; J G Jacobs; G Harris; T M Nett
Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
The Prostate 1995;26(2):55-71.
1995: Michael R Goldberg; T E Bradstreet; E J McWilliams; Wesley Tanaka; S Lipert; TD Bjornsson; Scott A Waldman; B Osborne; L Pivadori; G Lewis
Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
Hypertension 1995;25(1):37-46.
1994: aimee dallob; N S Sadick; WALTER UNGER; S Lipert; L A Geissler; S L Gregoire; H H Nguyen; E C Moore; Wesley Tanaka
The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.
The Journal of clinical endocrinology and metabolism 1994;79(3):703-6.
1994: M Depré; B Friedman; Anne Van Hecken; Inge De Lepeleire; Wesley Tanaka; aimee dallob; S Shingo; Arturo G Porras; C Lin; Paul De Schepper
Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.
Clinical pharmacology and therapeutics 1994;56(1):22-30.
1993: Brian J Ledwith; M K Cahill; L S Losse; S M Satiritz; R S Eydelloth; aimee dallob; Wesley Tanaka; Sheila M Galloway; W W Nichols
Measurement of plasma angiotensin II: purification by cation-exchange chromatography.
Analytical biochemistry 1993;213(2):349-55.
1993: Michael R Goldberg; Wesley Tanaka; A Barchowsky; T E Bradstreet; Jacqueline B McCrea; Man-Wai Lo; E J McWilliams; TD Bjornsson
Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Hypertension 1993;21(5):704-13.
1993: M Depre; B Friedman; Wesley Tanaka; Anne Van Hecken; A Buntinx; P J DeSchepper
Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.
Clinical pharmacology and therapeutics 1993;53(5):602-7.
1993: B S Friedman; Elisabeth H Bel; A Buntinx; Wesley Tanaka; Y H Han; S Shingo; R Spector; Peter J Sterk
Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses.
The American review of respiratory disease 1993;147(4):839-44.
1991: Elke M G J de Jong; I M van Vlijmen; J C Scholte; A Buntinx; B Friedman; Wesley Tanaka; P C M van de Kerkhof
Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis.
Skin pharmacology : the official journal of the Skin Pharmacology Society 1991;4(4):278-85.